Skip to main content

Table 2 Dynamic disease activity indicators and serum MMP-3 during one year follow-up

From: Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study

Disease activity indicators   1st month 3rd month 6th month 12th month
28TJC, median (IQR) 4 (1 ~ 9)*** 2 (0 ~ 4)*** 0 (0 ~ 4)*** 1 (0 ~ 5)***
28SJC, median (IQR) 2 (0 ~ 4)*** 0 (0 ~ 3)*** 0 (0 ~ 1)*** 0 (0 ~ 1)***
Pain VAS, median (IQR) 2.0 (1.7 ~ 4.0)*** 2.0 (0 ~ 3.0)*** 1.0 (0 ~ 2.8)*** 1.0 (0 ~ 3.0)***
PtGA, median (IQR) 3.0 (3.0 ~ 5.0)*** 3.0 (1.0 ~ 4.0)*** 2.0 (0.3 ~ 3.0)*** 2.0 (0 ~ 3.8)***
PrGA, median (IQR) 3.0 (2.3 ~ 4.0)*** 2.0 (1.0 ~ 4.0)*** 2.0 (0 ~ 3.0)*** 2.0 (0 ~ 3.0)***
HAQ, median (IQR) 0.28 (0 ~ 0.94)*** 0.15 (0 ~ 0.50)*** 0 (0 ~ 0.25)*** 0 (0 ~ 0.46)***
CRP, mg/dl, median (IQR) 0.44 (0.33 ~ 1.19)*** 0.33 (0.30 ~ 0.95))*** 0.34 (0.18 ~ 0.49)*** 0.33 (0.30 ~ 0.89)***
 Normal CRPa, % 54 59 77 70
ESR, mm/h, median (IQR) 34 (18 ~ 48)*** 29 (16 ~ 38)*** 21 (15 ~ 36)*** 26 (13 ~ 42)***
 Norma ESRb, % 27 38 41 39
DAS28c, median (IQR) 3.5 (2.6 ~ 4.4)*** 2.7 (2.0 ~ 3.9)*** 2.2 (1.5 ~ 3.2)*** 2.6 (1.5 ~ 3.3)***
 Remission, % 27 43 53 48
LDA, % 20 20 20 21
 MDA, % 44 30 20 26
HDA, % 9 7 7 5
SDAId, median (IQR) 14.5 (7.6 ~ 24.2)*** 8.9 (4.1 ~ 17.5)*** 5.3 (1.0 ~ 12.0)*** 6.4 (0.3 ~ 12.3)***
 Remission, % 7 18 39 34
 LDA, % 34 41 36 38
 MDA, % 38 30 16 19
 HDA, % 21 11 9 9
CDAIe, median (IQR) 13.7 (7.1 ~ 22.8)*** 8.0 (4.0 ~ 15.9)*** 4.5 (1.0 ~ 11.5)*** 5.5 (0 ~ 11.0)***
 Remission, % 7 18 39 38
 LDA, % 34 45 36 36
 MDA, % 34 26 16 16
 HDA, % 25 11 9 11
Serum MMP-3, ng/ml, median (IQR) 112 (49 ~ 347) 130 (32 ~ 183) 74 (32 ~ 183)* 52 (32 ~ 116)***
 Normal serum MMP-3f, % 32 38 46 62
RF, mg/ml, median (IQR) 119 (39 ~ 252)*** 72 (20 ~ 169)*** 49 (14 ~ 137)*** 78(16 ~ 142)***
Anti-CCP, U/ml, median (IQR) 85 (11 ~ 300)** 53 (13 ~ 296)*** 65 (16 ~ 297)** 112(14 ~ 300)*
  1. Pain VAS pain visual analogue scale, 28TJC 28-joint tender joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity, PrGA provider global assessment of disease activity, HAQ health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Disease Activity Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index, LDA low disease activity, MDA moderate disease activity, HDA high disease activity, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody
  2. *P < 0.05, **P < 0.01, ***P < 0.001. Compared between each time point and baseline by Wilcoxon matched-pairs signed ranks sum test
  3. anormal CRP: <0.5 mg/dl; bnormal ESR: <20 mm/h (female) or <15 mm/h (male); cDAS28-remission: <2.6; DAS28-LDA:2.6 ~ 3.2, DAS28-MDA:3.2 ~ 5.1, DAS28-HDA:>5.1; dSDAI-remission: <3.3; SDAI-LDA: 3.3 ~ 11.0, SDAI-MDA: 11.0 ~ 26.0, SDAI-HDA: >26.0; eCDAI-remission: <2.8; CDAI-LDA: 2.8 ~ 10.0, CDAI-MDA: 10.0 ~ 22.0, CDAI-HDA: >22.0; fnormal serum MMP-3: <60 ng/ml (female) or <120 ng/ml (male)